Biosimilar Red Tape Elimination Act

This bill changes how biosimilar drugs are approved by automatically considering them interchangeable with brand-name drugs, removing a previous requirement for separate approval. It requires the FDA to brief congressional health committees before demanding certain safety studies on switching between biosimilars and reference drugs. The law affects drug manufacturers seeking FDA approval for biosimilars and the FDA itself. These changes apply only to new applications approved after the bill's enactment.